2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. c-Fms

c-Fms

CSF-1 receptor; colony stimulating factor 1 receptor; CSF-1R; CSF1R

c-Fms

Related Products

PDF 0.51 MB

c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. c-FMS is the cell surface receptor for IL-34 and CSF1. c-FMS has important roles in haematopoiesis, regulation of proliferation, cell survival and maturation of microglia and monocytes, as well as in controlling the overall immune response.

c-FMS is specifically expressed in osteoclasts and myelomonocytic-lineage cells, such as monocytes and macrophages, and the activation of c-FMS signaling promotes the proliferation or differentiation of these cells. It also promotes the production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL6).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147609
    CSF1R-IN-8
    		Inhibitor
    CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor with an IC50 of 0.012 μM.
    CSF1R-IN-8
  • HY-153920A
    Pimicotinib hydrochloride
    		Inhibitor
    Pimicotinib hydrochloride is a CSF1R inhibitor with antitumor activity.
    Pimicotinib hydrochloride
  • HY-162415
    CSF1R-IN-22
    		Inhibitor
    CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC50<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8+ T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8+ T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs.
    CSF1R-IN-22
  • HY-147616
    CSF1R-IN-13
    CSF1R-IN-13 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32).
    CSF1R-IN-13
  • HY-161084
    CSF1R-IN-18
    		Inhibitor
    CSF1R-IN-18 (Compdound 16t), para-aniline derivative, is a colony-stimulating factor 1 receptor (CSF1R) inhibitor. CSF1R-IN-18 can be used for the research of cancers, CNS-diseases and bone diseases.
    CSF1R-IN-18
  • HY-13838A
    PLX647 dihydrochloride
    		Inhibitor
    PLX647 dihydrochloride is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC50s of 28 and 16 nM, reapectively. PLX647 dihydrochloride shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and VEGFR2/KDR/Flk-1 (IC50s=91 and 130 nM, respectively).
    PLX647 dihydrochloride
  • HY-147611
    CSF1R-IN-10
    		Inhibitor
    CSF1R-IN-10 (Compound 48) is a CSF-1R inhibitor with an IC50 of 0.005 μM.
    CSF1R-IN-10
  • HY-109086A
    Edicotinib hydrochloride
    		Inhibitor
    Edicotinib hydrochloride is a potent, selective, brain penetrant and orally active?colony-stimulating factor-1 receptor (CSF-1R)?inhibitor with an IC50 of 3.2 nM. Edicotinib hydrochloride exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively. Edicotinib hydrochloride limits microglial expansion and attenuates microglial proliferation and neurodegeneration?in mice. Edicotinib hydrochloride has the potential for Alzheimer’s disease and rheumatoid arthritis research.
    Edicotinib hydrochloride
  • HY-151377
    RET-IN-19
    		Inhibitor
    RET-IN-19 (compound 59) is a potent RET inhibitor, with IC50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research.
    RET-IN-19
  • HY-128680
    c-Fms-IN-9
    		Inhibitor
    c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT with IC50s of <0.01 μM and 0.1-1 μM, respectively.
    c-Fms-IN-9
  • HY-157996
    CSF1R-IN-21
    		Inhibitor
    CSF1R-IN-21 (compound 7e) is a CSF-1R Inhibitor with an IC50 value of 31 nM. CSF1R-IN-21 inhibits CSF-1R auto-phosphorylation and can be used for the research of neurodegenerative diseases .
    CSF1R-IN-21
  • HY-161706
    c-Fms-IN-15
    		Inhibitor
    c-Fms-IN-15 (compound 8g) is a potent inhibitor of FMS kinase, with the IC50 of 563 nM.
    c-Fms-IN-15
  • HY-158050
    PXB17
    		Inhibitor
    PXB17 can inhibit CSF1R (IC50 = 1.7 nM) by blocking the activation of PI3K/ AKT/mTORC1 signaling. PXB17 is orally effective. PXB17 significantly inhibits the growth of CRC, improves PD-1 mAb efficacy and reduces tumor recurrence in CRC.
    PXB17
  • HY-111947
    c-Fms-IN-6
    		Inhibitor
    c-Fms-IN-6 is a potent inhibitor of c-FMS, with an IC50 of ≤10 nM for unphosphorylated c-FMS, also weakly inhibits unphosphorylated c-KIT and PDGFR (IC50, > 1 μM). Used in the research of autoimmune diseases.
    c-Fms-IN-6
  • HY-139996
    Pomalidomide-C5-Dovitinib
    		Inhibitor
    Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells. Pomalidomide-C5-Dovitinib induces the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely blocks their downstream signaling pathway. Pomalidomide-C5-Dovitinib has the potential for the research of FLT3-ITD+ acute myeloid leukemia.
    Pomalidomide-C5-Dovitinib
  • HY-144042
    CSF1R-IN-6
    CSF1R-IN-6 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-6 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-6 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 5).
    CSF1R-IN-6
  • HY-162309
    CSF1R-IN-20
    		Inhibitor
    CSF1R-IN-20 (compound 7a) is a CSF-1R Inhibitor with an IC50 value of 467 nM. CSF1R-IN-20 inhibits CSF-1R auto-phosphorylation.
    CSF1R-IN-20
  • HY-155001
    CSF1R-IN-15
    		Inhibitor
    CSF1R-IN-15 (compound 23) is an inhibitor targeting CSF1R. The colony-stimulating factor-1 receptor (CSF1R) is a tyrosine kinase embedded in the cell membrane of macrophages. The receptor is activated by colony-stimulating factor-1 (CSF-1) and interleukin-34, and signaling via CSF1R is crucial for the differentiation, proliferation, and survival of macrophages.
    CSF1R-IN-15
  • HY-111948
    c-Fms-IN-7
    		Inhibitor
    c-Fms-IN-7 is a cFMS inhibitor extracted from patent WO2011079076A1, example159, has an IC50 of 18.5 nM.
    c-Fms-IN-7
  • HY-156556
    c-Fms-IN-14
    		Inhibitor
    c-Fms-IN-14 (Example 76) is a c-Fms inhibitor with an IC50 value of 4 nM. c-Fms-IN-14 can be used for research of cancer and autoimmune diseases.
    c-Fms-IN-14
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity